Combo listed after PBAC mix-up

Posted 2 June 2023 AM

After more than a year of working through challenges posed by a problematic PBAC recommendation, the first PD-1 inhibitor combination treatment for endometrial cancer has been subsidised on the PBS.

MSD's Keytruda in combination with Eisai's Lenvima is now subsidised for eligible women with advanced, metastatic, or recurrent endometrial carcinoma via the PBS as an option following treatment with chemotherapy. If a patient has an intolerance or contraindication to Lenvima, Keytruda can be prescribed as a monotherapy.

To see the whole article, please login